The cholesterol-sensing nuclear receptor liver X receptor (LXR) and the glucose-sensing transcription factor carbohydrate responsive element-binding protein (ChREBP) are central players in regulating glucose and lipid metabolism in liver. We have previously shown that LXR regulates ChREBP transcription and activity; however, the underlying mechanisms are unclear. In the current study, we demonstrate that LXRα and ChREBPα interact physically, and show a high co-occupancy at regulatory regions in the mouse genome. LXRα co-activates ChREBPα, and regulates ChREBP-specific target genes in vitro and in vivo. This co-activation is dependent on functional recognition elements for ChREBP, but not for LXR, indicating that ChREBPα recruits LXRα to chromatin in trans. The two factors interact via their key activation domains; ChREBPα's low glucose inhibitory domain (LID) and the ligand-binding domain (LBD) of LXRα. While unliganded LXRα co-activates ChREBPα, ligand-bound LXRα surprisingly represses ChREBPα activity on ChREBP-specific target genes. Mechanistically, this is due to a destabilized LXRα:ChREBPα interaction, leading to reduced ChREBP-binding to chromatin and restricted activation of glycolytic and lipogenic target genes. This liganddriven molecular switch highlights an unappreciated role of LXRα that was overlooked due to LXR lipogenesis-promoting function.
INTRODUCTION
Glucose and lipid metabolism are tightly connected and coordinately regulated in mammals to maintain whole-body energy homeostasis. In the liver, excess dietary carbohydrates are converted to fatty acids through de novo lipogenesis (DNL) destined for long-term storage as triglycerides in adipose tissue. Dysregulation of lipogenesis contributes to non-alcoholic fatty liver disease (NAFLD), which is associated with increased risk of metabolic syndrome and type 2 diabetes (Ballestri et al, 2016 , Samuel & Shulman, 2018 . Several transcription factors (TFs) play essential roles in modulating glucose and lipid metabolism, including the cholesterolsensing nuclear receptor liver X receptor (LXR), and the glucose-sensing TF carbohydrate responsive element-binding protein (ChREBP) , Poupeau & Postic, 2011 .
While showing high sequence homology, the two LXR isoforms differ in their distribution (reviewed in (Jakobsson et al, 2012) ): LXRα is predominantly expressed in metabolically active tissues, e.g. liver and adipose tissue, while LXRβ is ubiquitously expressed . Both isoforms heterodimerize with retinoic X receptors (RXRs), and regulate expression of genes involved in cholesterol homeostasis, lipid and glucose metabolism, and inflammation (A-Gonzalez et al, 2009 , Jakobsson et al, 2012 , Laffitte et al, 2003 , Schultz et al, 2000 , Zhang et al, 2012 , by binding to LXR response elements (LXREs; two direct repeats AGGTCA spaced by four nucleotides, DR4 elements) in gene regulatory regions (Willy et al, 1995) . In vivo LXR transactivity is modulated by oxysterols (oxidized cholesterol derivatives), which bind to the ligand-binding domain (LBD) of LXR (Janowski et al, 1996) . This elicits conformational changes in LBD which leads to the release of corepressors, recruitment of co-activators, and initiation of target gene transcription (Hu et al, 2003 , Jin & Li, 2010 , Svensson et al, 2003 . By functioning as a 'cholesterol sensor', LXR can integrate metabolic signals into complex transcriptional responses: In the liver LXR responds to cholesterol, insulin, and glucose in the form of O-linked β-N-acetylglucosamine (O-GlcNAc) (Anthonisen et al, 2010 , Bindesboll et al, 2015 , Chen et al, 2004 , Janowski et al, 1996 , by activating the transcription of ChREBP and sterol regulatory element-binding protein (SREBP)-1c (Cha & Repa, 2007 , Repa et al, 2000a , which alone or together with LXR induce the transcription of glycolytic and lipogenic enzymes, such as liver pyruvate kinase (Lpk), acetyl-CoA carboxylase (Acc), fatty acid synthase (Fasn), and stearoyl-CoA desaturase-1 (Scd1) (Filhoulaud et al, 2013 , Repa et al, 2000a , Talukdar & Hillgartner, 2006 . This leads to increased de novo synthesis of fatty acids. Several synthetic ligands targeting LXR have been interaction could be detected at the genomic level. To determine this, we reanalyzed two published chromatin immunoprecipitation sequencing (ChIP-seq) datasets; one ChREBP ChIPseq performed in livers from mice fasted and refed a high-carbohydrate diet (Poungvarin et al, 2015) and one LXR ChIP-seq done in livers from mice treated with the LXR agonist T0901317 (Boergesen et al, 2012) . The sequence reads were mapped to the mouse genome generating a genome-wide, high-resolution map of ChREBP and LXR binding sites. We detected 48,647 and 24,728 binding sites for ChREBP and LXR, respectively.
Using the top 20,000 ChREBP peaks and all the LXR peaks we calculated the peak(ChREBP)-to-peak(LXR) distance for all peaks. Interestingly, as many as 11,022 peak pairs showed a peak-to-peak distance of less than 1,000 bp, and 7,928 (71.9%) of these were less than 100 bp apart ( Figure 1B) . Given the resolution of these datasets, all peaks less than 100 bp apart are likely to represent co-localized peaks, indicating that ChREBP and LXR occupy many of the same loci and that co-occupancy within these regions is high ( Figure 1D ). We also found that the peak pairs clustered around transcription start sites (TSSs), with the expected depletion at TSS ( Figure 1C ). The peak pairs which represent peaks less than 100 bp apart were located both upstream and downstream of TSS. However, we found that peak pairs of bona fide LXR or ChREBP target genes (blue dots) located mainly upstream or near the TSS, consistent with the notion that most TF binding sites are found upstream of TSSs (Koudritsky & Domany, 2008 , Xie et al, 2005 . As an example, the two ChREBP target genes Lpk and Chrebpβ showed significant ChREBP enrichment at the expected sites in the respective promoters, and LXR co-occupied the same sites ( Figure 1E ). Looking at the genomic position of all peak pairs, independent of distance to TSS using Rgmatch 7 (https://bitbucket.org/pfurio/rgmatch), we found the peak pairs to be distributed throughout the genome like other NRs (Boergesen et al, 2012 , Chong et al, 2010 , Stender et al, 2010 .
Specifically, 39% of them seem to cluster around TSSs ( Figure 1F ; Promoter-TSS-First Exon-First Intron).
To assess how the seemingly high genome-wide co-occupancy of ChREBP and LXR compared with the co-occupancy between other hepatic TFs, we reanalyzed ChIP-seq data of mouse peroxisome proliferator-activated receptor-α (PPARα) and farnesoid X receptor (FXR) (Boergesen et al, 2012 , Ijssennagger et al, 2016 . We next calculated the Forbes coefficients (FC), evaluating genomic co-occurrence while correcting for genome coverage (Salvatore et al, 2019) . Both PPARα and FXR are known to co-occupy genomic loci and/or interact with LXR and ChREBP (Boergesen et al, 2012 , Caron et al, 2013 , Ide et al, 2003 , Trabelsi et al, 2015 .
PPARα and LXR showed the highest similar score among all compared TFs (FC: 136.7; Figure   1G ), in line with published data (Boergesen et al, 2012) . ChREBP and LXR shared the second highest genomic co-occurrence, with a FC of 133.7 ( Figure 1G ). FXR was recently reported to physically interact with ChREBP, negatively regulating ChREBP activity (Caron et al, 2013) .
Thus, it was somewhat unexpected to see that FXR shared a significantly smaller portion of the genome with ChREBP than LXR did (FC: 57.5; Figure 1G ).
Finally, we performed gene set enrichment analysis (GSEA) based on the Reactome Pathway Database. We analyzed genes with ChREBP-LXR peak pairs residing either in the promoter, around the TSS or in the first exon, and with a peak-to-peak-distance < 100 bp (corresponding to peak pairs between -5000 to +2500 bp from the TSS). As expected, the filtered genes were enriched in pathways regulated by both ChREBP and LXR, e.g. metabolism of lipids, fatty acids and glucose (Table 1) . Notably, pathways involved in metabolism of amino acids, γ-carboxylation, and coagulation, which has not been described to be regulated by ChREBP nor LXR, were also enriched in the gene set. This suggests potential novel biological functions regulated through the concomitant binding of ChREBP and LXR.
LXRα and ChREBPα co-activates ChREBP target genes in vitro and in vivo
Having established that ChREBPα and LXRα interact and that they co-occupy regulatory regions in the mouse liver genome, we addressed the transcriptional effects of this interaction in reporter gene assays using two luciferase reporter constructs driven by the mouse Chrebpβ promoter (Herman et al, 2012) and the rat Lpk promoter (Thompson & Towle, 1991) . LXR was always co-transfected with its dimerization partner RXRα, and ChREBP with its dimerization partner Mlxγ, unless otherwise stated. As expected ChREBPα:Mlxγ were able to induce the transcription from both reporters in the human hepatocarcinoma cell line Huh7 (Figure 2A ).
Moreover, ChREBPα transactivation of the Chrebpβ promoter increased three-fold when the glucose concentration in the media was augmented from 2.5 mM to 25 mM (Figure 2A ). This is consistent with data from the seminal ChREBPβ study by Herman and coworkers (Herman et al, 2012) . Interestingly, LXRα:RXRα seemed to be able to upregulate the transcriptional activity from both promoters, and ChREBPα and LXRα together showed a synergistic effect on the transcriptional activity ( Figure 2A ). To exclude the potential impact of RXRα in regulating these constructs, we examined RXR and LXR separately, and observed no induction of Chrebpβ promoter activity from either RXRα or LXRα alone (suppl. Figure 1A ). In the following in vitro experiments, we chose to keep the glucose concentration at 25 mM to ensure a high ChREBPα activity, unless otherwise stated.
To investigate the impact of the different LXR isoforms, LXRα and LXRβ, on ChREBP activity in vivo, we performed fasting-refeeding experiments with wild-type (WT), LXRα -/-, LXRβ -/and LXRα -/β -/-(double knockout, DOKO) mice. The mice were fasted for 24 hours, or fasted for 24 hours and refed for 12 hours before they were sacrificed. Liver from 5-8 animal per genotype were examined. The feeding-induced hepatic expression of the ChREBP specific target genes Lpk and Chrebpβ was significantly reduced in LXRα -/and DOKO mice, but not in LXRβ -/mice ( Figure 2B ). On the contrary, no significant changes in Chrebpα expression was observed, suggesting that LXRα, but not LXRβ, is essential to regulate ChREBP activity.
This conclusion was substantiated in reporter gene assays, showing no activation of the
Chrebpβ promoter by LXRβ, and no synergistic effect when co-expressing LXRβ and ChREBPα (suppl. Figure 1A and B). Taken together, these results demonstrate that LXRα, but not LXRβ, co-activates the expression of ChREBP-specific target genes in vitro and in vivo together with ChREBPα.
LXRα:ChREBPα co-activation requires functional ChoREs but not LXREs
LXR and ChREBP share many transcriptional targets, e.g. the DNL genes Acc, Fasn, Scd1, which contain both LXREs and ChoREs in their promoter/regulatory regions (Filhoulaud et al, 2013 , Line M. Grønning-Wang, 2013 deletion scan showing no effect on the promoter activity (suppl. Figure 1C and D; DR4 del).
We also remapped the functional ChoRE in the Chrebpβ exon 1B promoter to the so-called "E-9 box-like" domain, 98 bases upstream of the TSS (suppl. Figure 1C and E) -a detail missed in the original ChREBPβ paper (Herman et al, 2012) . Nonetheless, despite no obvious LXRE,
LXRα was able to activate the reporters together with ChREBPα ( Figure 2A ). We therefore investigated the impact of ChoREs and LXREs on LXRα:ChREBPα co-activation by designing three synthetic luciferase reporters: one containing two canonical ChoREs and two canonical LXREs, one that contained only the two ChoREs and one that only contained the two LXREs.
The order (ChoRE-LXRE-ChoRE-LXRE) and the phasing (20 bp) of the recognition elements was kept constant ( Figure 3A ) to make sure that the TFs would adopt the same rotational orientation in all three constructs, as this has been shown to greatly impact transactivity on compound promoters (Molvaersmyr et al, 2010) . To ensure an acceptable read-out from the synthetic promoters, we turned to the constitutively active forms of ChREBP; ChREBPβ and ChREBP-Q. While ChREBPβ is a naturally occurring isoform lacking the LID, ChREBP-Q is a ChREBPα quadruple mutant H51A/S56D/ F90A/N278A that has escaped the low-glucose inhibition while keeping the N-terminal domain (Davies et al, 2010) . As expected, a synergistic co-activation was observed with both LXRα/ChREBP-Q and LXRα/ChREBPβ on the ChoRE+LXRE reporter ( Figure 3B ), reflecting the situation on a dual LXR/ChREBP target gene. Interestingly, this pattern was retained on the ChoRE-only reporter, but only with LXRα and ChREBP-Q. ChREBPβ seemed to have lost the ability to co-activate with LXRα in this context, mimicking a ChREBP-specific target gene ( Figure 3B ). This was not due to different abilities to bind to the promoter, as evaluated by ChIP (suppl. Figure 2A ). The effect was even more dramatic on the LXRE-only reporter where neither ChREBP-Q nor ChREBPβ was able to activate, even though LXR still transactivated the promoter (suppl. Figure 2B ). This indicates that ChoREs, but not LXREs, are sufficient to support LXRα:ChREBPα co-activation and that only full-length ChREBP, i.e. not ChREBPβ, is co-activated by LXRα on ChoRE-only target genes. To assess this on natural promoters we used the ChREBP-specific, ChoRE-only Chrebpβ and Lpk-driven reporters. Again, the same pattern emerged: LXRα was able to co-activate ChREBPα and ChREBP-Q, but not ChREBPβ that lacks most of the LID ( Figure 3C ).
LXRα and ChREBPα interact via key activation domains
The ability of LXRα to co-activate ChREBPα in an LXRE-independent manner naturally brought up the question of that what domains of LXRα and ChREBPα are involved in their interaction. We therefore examined the interaction between full-length LXR and ChREBP and different truncations using CoIP. ChREBPα interacted with LXRα when immunoprecipitating both ways ( Figure 1A and 4A ). On the other hand, and in line with the gene expression data ( Figure 3 ), ChREBPβ did not bind to LXRα as neither ChREBPβ nor LXRα was able to coimmunoprecipitate with each other ( Figure 4A ). ChREBPβ lacks the first 177 amino acids (aa) in the N-terminal, which form most of the LID in ChREBPα. Hence, we constructed a ChREBP truncation that only expressed the first 177 residues, i.e. the LID. This domain bound strongly to LXRα, and seemed sufficient to support the interaction between the full-length factors ( Figure 4A ). Furthermore, we examined the interactions among ChREBPα and different LXRα truncations. ChREBPα interacted with the LXRα C-terminus, including its hinge domain and LBD ( Figure 4B ). In addition, ChREBPα also interacted with LXRβ (suppl. Figure 3 ), although this interaction seems to be less relevant in liver ( Figure 2B and suppl. Figure 1A and B).
ChREBPα was previously shown to interact with FXR, with one of the interaction surfaces residing in its LBD (Caron et al, 2013) . Multiple sequence alignment using ClustalX (http://www.clustal.org/clustal2) revealed that LXRα, LXRβ and FXR show high similarity in multiple patches throughout the LBD (data not shown), suggesting that LXRα might use a similar interface when binding to ChREBPα.
To expand on the consequences of the ChREBP:LXR interaction in a functional context, we asked whether LXRα is dependent on binding to DNA to induce the activity of ChREBPα on ChREBP target genes, given that the interaction seem to run via LID and LBD. To this end, we constructed an LXRα DNA binding mutant (DBDm), in which two cysteines (C115 and C118) in the first DBD zinc finger were mutated to alanine to abrogate DNA binding. The LXRα DBD mutant had lost its ability to transactivate the Srebp1c promoter as well as the Lpk promoter (suppl. Figure 4A and B), the former being a well-established LXR target gene (Yoshikawa et al, 2001) . Peculiarly, the LXRα DBDm also lacked the ability to co-activate ChREBPα, arguing that DNA binding or rather DBD integrity is important for the full coactivation effect of LXR (suppl. Figure 4B ). This is in line with what we observed in Figure 3B , where the promoter LXRE was mutated and the reporter output amplitude dropped while the regulation pattern was retained. Moreover, it contrasts with the loss of co-regulation seen when the ChoRE was mutated (suppl. Figure 4B , right panel; Figure 3B , right panel). Taken together, our data suggest that ChREBPα and LXRα interact via key regulatory domains, namely the Nterminal LID of ChREBPα and the C-terminal, LBD-containing part of LXRα. This assigns a novel function to the ChREBP LID in physically bridging the two factors, allowing LXRα to co-activate ChREBPα on ChREBP-specific target genes.
Ligand-activated LXRα represses ChREBPα activity on ChREBP-specific target genes 11
The physical interaction and co-regulatory interplay between ChREBPα and LXRα led us to ask how this affects gene expression in a fully chromatinized context. To investigate this, we isolated primary mouse hepatocytes and cultivated them for 24 hours in either low glucose (1 mM) or high glucose (25 mM) to induce ChREBP activity, and concomitantly stimulated them with the potent, selective LXR agonist GW3965 (10 M) to induce LXR-activity. The DNL genes Acacb, Fasn and Scd1, which are common targets of LXR and ChREBP, were significantly upregulated by the LXR agonist ( Figure 5A ). The expression of ChREBP-specific target genes Chrebpβ, Lpk, Txnip and Rgs16 on the other hand showed a dramatically different pattern ( Figure 5B ): These genes were upregulated by high glucose treatment, while the LXR agonist surprisingly displayed a repressive effect under high glucose conditions. This was also seen with the Chrebpβ reporter (suppl. Figure 5A ). To exclude a possible GW3965 peculiarity, we recapitulated this experiment with the same outcome using Tularik (T0901317), another LXR agonist, both in primary hepatocytes and by transfecting the ChREBP-specific Lpk reporter in Huh7 cells (suppl. Figure 5A and B). These data reveal that ligand-activated LXRα plays distinct roles on different groups of genes, activating common targets of LXR and ChREBP, while repressing ChREBP-specific target genes.
Ligand-activated LXRα reduces ChREBP binding to chromatin
To try to untangle the mechanism underlying the LXR ligand-dependent repressive effect, we performed ChIP assays to study ChREBPα and LXRα chromatin binding dynamics in the noncancerous, mouse hepatocyte cell line AML12. Based on our analysis of the ChIP-seq datasets ( Figure 1 ), we selected four gene loci that are co-occupied by ChREBP and LXR in the promoter region: the ChREBP-specific targets Lpk and Txnip, and the common LXR and ChREBP targets Fasn and Scd1 ( Figure 6A ). The Mlxipl exon1b promoter was excluded from these analyses due to low expression of ChREBPβ in AML12 cells (data not shown). In the presence of ChREBPα, all four promoters were robustly immunoprecipitated. Moreover, LXRα did not affect ChREBPα occupancy on any of the promoters (suppl. Figure 6A ). Conversely, ChREBPα increased the binding of LXRα on the same promoters (suppl. Figure 6B ), in line with the notion that ChREBPα is able to recruit LXRα to ChoREs via the LID-LBD interaction ( Figures 3 and 4 ).
When the same cells transfected with both ChREBPα and LXRα were treated with LXR agonist GW3965, ChREBPα-binding to chromatin was reduced on all four promoters ( Figure   6A ). Concomitantly, a weak, non-significant reduction was observed for LXRα occupancy.
Supporting these observations, GW3965 treatment reduced the ChREBPα:LXRα interaction ( Figure 6B ), suggesting that a ligand-induced conformational change in LXRα LBD reduces its affinity for ChREBPα. Loss of LXR from the complex weakens ChREBPα's ability to bind chromatin. This likely has the most dramatic effect on ChREBP-specific target genes, like Lpk and Txnip, where the LXR binding to the promoter chromatin is mediated through ChREBP ( Figure 6A left panel) . Common LXR and ChREBP target gene promoters, like Fasn and Scd1, should still be able to accommodate both factors ( Figure 6A ). Altogether, this results in the reduced expression of ChREBP-specific targets genes seen in Figure 4B . This echoes the lost ChoRE binding and lost feeding-induced expression of ChREBP-specific target genes we previously reported with the LXR double knockout mice (Bindesboll et al, 2015) . The current data broaden this picture, showing that LXR ligand engagement modulates ChREBPα:LXRα interaction, chromatin occupancy, and target gene co-activation.
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DISCUSSION
Altogether, our findings argue for a close collaboration between LXRα and ChREBPα in regulating glycolytic and lipogenic genes. Hence we propose a new model (Figure 7) Repa, 2007) . Since then the idea has been that LXR, in addition to regulating its own direct target genes, indirectly contributes to the induction of ChREBP regulated glycolytic and lipogenic target genes. However, in this study we show that the picture is more complex. In addition to upregulating Chrebpα expression by binding to This was recently also demonstrated for Rev-erbα, which is tethered to chromatin by hepatic lineage determining TFs (Zhang et al, 2015) . DBD-independent functions like these might explain non-overlapping cistromes and/or transcriptomes in different cell types (Boergesen et al, 2012 , Heinz et al, 2010 . A relocation of LXR from trans-coactivation complexes on
ChREBP-specific target genes to classical ligand-engaged RXR heterodimers on LXR-specific target genes is also in line with the type of TF-cofactor redistribution described for NFκB (Schmidt et al, 2015) and PPARγ (Step et al, 2014 ). An LXR-driven redistribution of coactivators from ChREBP-specific to LXR-specific promoters, would also explain the liganddependent repression observed in our study.
Posttranslational modification by small ubiquitin-like modifier (SUMO) of TFs and coregulators is generally linked to transcriptional repression (Flotho & Melchior, 2013) , and
SUMOylation of LXRs and PPARγ appears to be required for transrepression in macrophages (Ghisletti et al, 2007) . Whether posttranslational modifications are involved in enforcing the LXRα:ChREBPα complex is not known. If so, O-GlcNAc modification, which derives from the metabolically integrated hexosamine biosynthetic pathway (HBP), might be a candidate.
LXR is posttranslationally O-GlcNAc modified in response to high glucose (Anthonisen et al, 2010 , Bindesboll et al, 2015 . The same is true for ChREBP, which leads to increased transcriptional activity and recruitment to target gene promoters (Guinez et al, 2011 , Sakiyama et al, 2010 . interacting with a coregulatory protein that plays a role in transcriptional activation in a step subsequent to glucose-dependent relief of repression (Davies et al, 2010) . In a bioinformatics sequence-structure analysis approach ChREBP was in fact suggested to interact with NRs, like
HNF4α and FXR, but through a nuclear receptor box (NRB) in the proline-rich region ( Figure   4A ), to support interaction between CBP/p300 and ChREBP MCR6 (McFerrin & Atchley, 2012) . Based on our data, we now propose LXRα to be the co-regulator hypothesized by Davies et al. (Davies et al, 2010) . Moreover, we confirm that ChREBPβ has escaped low-glucose control, and we expand this to include negative regulation by liganded LXR. As a consequence
ChREBPβ acts as an extremely potent effector of carbohydrate signals through its feed-forward relationship with ChREBPα and so it is no surprise that its expression levels and stability is 15 much lower than ChREBPα. This has been described before (Herman et al, 2012 , Jing et al, 2016 and is confirmed in our study (Figure 4) .
The high genome-wide co-occupancy of LXR and ChREBP observed in the ChIP-seq data was rather surprising: More than 71% of ChREBP-LXR peak pairs have peaks less than 100 bp apart ( Figure 1B ), suggesting full co-localization at these sites. A similar frequency of overlapping LXR peaks had been reported before by Boergesen et al. for LXR and PPAR, on non-canonical LXR/PPAR recognition elements (DR4 or DR1) (Boergesen et al, 2012) . The existence of LXR-PPARα heterodimers has been suggested earlier (Ide et al, 2003) , but the authors found no evidence for such transcriptional complexes. Instead they concluded that the receptors bound to the same degenerate elements, representing NR binding hot spots (Siersbaek et al, 2011) , in a mutually exclusive manner (Boergesen et al, 2012) . In our study, on the other hand, many of the overlapping LXR and ChREBP peaks are found on or adjacent to ChoREs (in e.g. Lpk, Chrebpβ, Tixnip, Rgs16), with no obvious LXRE/DR4 close by. In addition, our data demonstrate a physical interaction between the factors and the ability of ChREBPα to recruit LXRα to the promoter ChoRE, but not the other way around. This points to a different mechanism underlying the ChREBP-LXR co-occupancy, where ChREBPα recruits LXRα in trans to ChoREs. Our data do not formally rule out the possibility that LXRα on certain sites also contacts chromatin directly, via its DBD, in addition to binding to ChREBPα via its LBD.
In fact, such ChREBP-LXR contacts might function as bridging point for smaller or larger chromatin loops (Mora et al, 2016 , West et al, 2002 , like promoter-enhancer loops (Siersbaek et al, 2017) , possibly within topologically associated domains (TADs) (Paulsen et al, 2019) . A tantalizing scenario could be that ChREBPα and LXRα are involved in bridging the exon 1A other hand, will activate LXR and drive cholesterol metabolism and efflux (Naik et al, 2006) .
In the liver acetyl-CoA generated from β-oxidation of saturated fatty acids (SFAs) is used in cholesterol biosynthesis. Thus, diets rich in SFAs and trans-FAs might cause excess levels of cholesterol that need to be excreted via the bile (Zhu et al, 2012) . While exogenous cholesterol contributes to the total, high cholesterol levels are often a result of, or secondary to, high levels of dietary SFAs. This puts some of our observations in an interesting perspective. In the case of a carbohydrate and lipid-rich condition, the liver receives both glucose and oxysterol cues, activating both glucose-driven lipogenesis and oxysterol-driven cholesterol excretion. LXRα, which activates both pathways, also functions as a molecular switch (Figure 7) . To prevent toxic accumulation of free cholesterol, de novo synthesized FAs is used to esterify cholesterol that are released as neutral cholesteryl esters in apoB-containing lipoproteins (Furbee et al, 2002 , Xie et al, 2002 . However, our data suggest that ligand-bound LXR will reduce the coactivation of glycolytic and lipogenic ChREBP target genes. Accordingly, LXRα might safeguard the liver against ectopic SFA levels. Alternatively, LXRα's activation-to-repression relay is part of a negative feedback mechanism, ensuring that the activation of ChREBPα, coactivation of Chrebpβ transcription, and subsequent induction of glycolytic and lipogenic genes is limited, when the local concentration of pyruvate, acetyl-CoA and SFAs, as well as cholesterol/oxysterol reaches a certain level. This hitherto unappreciated role of LXRα may have been overlooked due to LXR's DNL-promoting function.
Several LXR-activating drugs have been developed through the years aiming at boosting reverse cholesterol transport (Naik et al, 2006 , Repa et al, 2000b . However, the use of such agonists has been hampered by their lipogenic effects, leading to hypertriglyceridemia and hepatic steatosis (Fievet & Staels, 2009 , Schultz et al, 2000 . As LXR seem to have both lipogenic-promoting and lipogenic-limiting effects, it is tempting to speculate if it is possible to separate the two. The success of such an effort would most probably lie in targeting both the DBD and LBD of LXRα, breaking the DNA:DBD contact (Leung et al, 2013 , Moore et al, 2010 ) and activating the LBD. Preliminary in vitro data using the LXR DBD-mutant in combination with GW3965 show that this might be one way to go.
MATERIALS AND METHODS
Materials
Formaldehyde ( 
ChIP-seq data analysis
Reads were mapped to the mm9 reference genome using BWA aln (version 0.7.17) with default parameters, and alignments with mapping quality less than 30 were discarded using Samtools filter (version 1.9). Peaks were called using MACS (version 2.1.1) with default parameters.
Peaks within mm9 blacklisted regions (Amemiya et al, 2019) were discarded. There were 48 647 ChREBP peaks detected, and the top 20 000 peaks with highest score were chosen for further analysis. There were 24 728 LXR peaks detected, all of which were chosen for further analysis.
Pairs of close ChREBP and LXR peaks were selected by running bedtools closest (version 2.26.0) on the peak summits of the ChREBP and LXR peaks, and discarding pairs of close peaks with summit-to-summit distance larger than 1000 base pairs. These pairs were linked to their nearest gene by running Rgmatch (Furio-Tari et al, 2016) with --report gene -distance 25 --promoter 5000 as parameters.
Similarity between binding sites of the different transcription factors ( Figure 1G) was measured by the Forbes coefficient (https://www.ideals.illinois.edu/handle/2142/55240) using the Genomic HyperBrowser (Sandve et al, 2010) .
Animals and fasting-refeeding experiments
LXRαβ wild type, LXRα -/-, LXRβ -/and LXRα -/β -/-(double knockout, DOKO) male mice were housed in a temperature-controlled (22 °C Schuster et al, 2002) .
Male mice aged 8-12 weeks (weight 25-30 g) were fasted for 24 hours (Fasted), or fasted for 24 hours and refed for 12 hours (Refed). All male littermates in a litter of correct age, weight and genotype were randomly allocated to a given treatment. No particular measures were taken to minimize subjective bias during group allocation. Each genotype-treatment group consisted of 5-8 animals, 53 mice in total, allowing us to detect 2-fold changes, given a coefficient of variation of 25% or less (Faul et al, 2007) . The mice were euthanized by cervical dislocation at the end of the dark period. Livers were dissected and rapidly frozen in liquid nitrogen and stored at -80°C until isolation of total RNA. The liver samples were coded and processed by two independent, blinded researchers during RNA sample preparation and qRT-PCR. All animal use was approved and registered by the Norwegian Animal Research authority and the regional ethical committee for animal experiments in Sweden.
Mouse primary hepatocytes isolation and culture
Mouse primary hepatocytes were isolated as previously described with modest changes (Arnesen et al, 2019) . Briefly, male C57BL/6N mice (Jackson Laboratory, Bar Harbor, ME, USA) aged 7-8 weeks were anaesthetized with isoflurane (AbbVie), before the livers were perfused via the portal vein with liver perfusion medium (#17701038, Thermo Fisher Scientific) for 15 min (2 mL/min) followed by liver digestion medium (#17703034, Thermo Fisher Scientific) for 15 min. The liver was then removed and dissociated in liver perfusion buffer before filtering through a 100 μm strainer (Thermo Fisher Scientific). Hepatocytes were washed 4 times with ice-cold low glucose DMEM (D6046; Sigma-Aldrich) supplemented with 10 mM Hepes (#15630080, Thermo Fisher Scientific), 5% charcoal stripped FBS (#12329782, Thermo
Fisher Scientific) and 1% penicillin-streptomycin (50 U/mL; 50 μg/mL). Hepatocytes were seeded as 2.5 × 10 5 cells/well onto type I collagen coated 12-well plates in attachment medium (William's E media, #12551032, Thermo Fisher Scientific) with 10% FBS, 1% penicillinstreptomycin and 10 nM insulin. The medium was changed 2 h after plating to overnight media consisting of low glucose DMEM (D6046; Sigma-Aldrich), 5% FBS, 1% penicillinstreptomycin and 1 nM insulin. On the next day, hepatocytes were washed twice with 1 mL medium/well consisting of DMEM with either 1 mM glucose (LG) or 25 mM glucose (HG), 5%
FBS, 1% penicillin-streptomycin and 1 nM insulin, and then cultured overnight in LG or HG medium supplemented with 0.1% DMSO, 10 µM GW3965, or 10 µM T0901317, respectively.
Hepatocytes were harvested after 18 hours treatment for RNA isolation.
Cell culture and transfection
Huh7 human liver hepatoma cells (Nakabayashi et al, 1982) 
Plasmids
The FLAG-tagged human or mouse LXR expressing plasmids pcDNA3-FLAG-hLXRα, pcDNA3-FLAG-hLXRβ and pcDNA3-FLAG-mLXRα, the untagged human RXRα expressing plasmid pcDNA3-hRXRα and the empty vector pcDNA3-FLAG have been described earlier (Anthonisen et al, 2010 , Weedon-Fekjaer et al, 2010 . To generate the pcDNA3-FLAG-hLXRα-DBD-mutant, two cysteine to alanine point mutations (C115A/C118A) in the DNA binding domain were introduced using the QuikChange Site-directed Mutagenesis kit (Agilent Genomics) and the primers listed in Supplementary Table 1 . The plasmids expressing mouse Mlxγ (pCMV4-HA-mMlxγ), ChREBPα (pCMV4-FLAG-mChREBPα) and ChREBPβ (pCMV4-FLAG-mChREBPβ), as well as the empty vector pCMV4, were received as generous gifts from Prof. Mark Herman (Herman et al, 2012) . To generate the ChREBPα LID expression plasmid, cDNA corresponding to the FLAG-tag, ChRBEPα amino acids 1-178, and a stop codon, was PCR amplified from pCMV4-FLAG-mChREBPα and subcloned into the pCMV4 vector using BglII and HindIII restriction enzymes. The plasmid expressing the ChREBP quadruple mutant (H51A/S56D/ F90A/N278A) (ChREBP-Q) was a kind gift from Prof. Em.
Howard Towle (Davies et al, 2010) .
The Chrebpβ promoter-driven luciferase reporter pGL3b-ChREBPβ-exon1b-luc (wildtype) and its mutants ChoRE+Ebox-del (both ChoRE and E-box deleted) and ChoRE-del 20 (ChoRE is deleted) were kind gifts from Prof. Mark Herman (Herman et al, 2012) . The pGL3b-ChREBPβ-exon1b-luc reporter mutants Ebox-del (E-box deleted) and DR4-del (candidate DR4 response element deleted) were generated by using the QuikChange Site-directed Mutagenesis kit (Agilent Genomics) and the primers listed in Supplementary Table 1 . The pGL3-rL-PK(-183)-luc (PK-luc) was a kind gift from Prof. Em. Howard Towle (Thompson & Towle, 1991) , and the ChoRE mutated reporter pGL3-rL-PK(-183)-Gal4-luc (PK-ChoREmut-luc) was a kind gift from Prof. Donald K. Scott (Collier et al, 2007) . The mouse SREBP-1c reporter pGL2basic/-550-mSREBP1c-prom-luc (SREBP1c-luc) was kindly provided by Prof. Nobuhiro
Yamada (Yoshikawa et al, 2001) .
The multimerized ChoRE and LXRE reporters: pGL3b-2xChoRE-2xLXRE-10 (ChoRE+LXRE-luc), pGL3b-2xChoRE-10 (ChoRE-only-luc), and pGL3b-2xLXRE-10
(LXRE-only-luc) were constructed in two steps: First, the 136 bp inserts were made by gene synthesis (GenScript, Nanjing, China). The SacI-BglII-lined inserts were designed to contain two canonical ChoREs (CACGTGatataCACGTG) and two canonical LXREs (AGGTCActctAGGTCA) in the order ChoRE-LXRE-ChoRE-LXRE, and with a spacing of 10 bp (gtaatattaa), giving a phasing of ~20 bp center to center between the REs. The inserts were then cut from the production vector pUC57 (GenScript) and subcloned into pGL3 basic vector between SacI and BglII. The schematic representation of synthetic reporters is illustrated in Figure 3A . The Renilla Luciferase reporter pRL-CMV (Promega, Madison, WI, USA) was used as internal control of transfection efficiency. All plasmids were verified by sequencing.
Luciferase reporter assay
Huh7 cells were seeded at density 7×10 the chromatin and rotated at 4°C for 2 hours. The Dynabeads were then washed three times with wash buffer 1 (0.1% SDS, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 20 mM Tris (pH 8)), followed by washing once in wash buffer 2 (0.1% SDS, 1% Triton X-100, 0.5 M NaCl, 1 mM EDTA, 20 mM Tris (pH 8)), once in wash buffer 3 (0.25 M LiCl, 1% NaDOC, 1% NP-40, 1 mM EDTA, 20 mM Tris (pH 8)), and finally once in wash buffer 1. All washing steps were done with rotation for 5 min at room temperature. DNA-protein complexes were eluted with 1% SDS and reverse cross-linked over night at 65°C. DNA was purified by using the QIAquick PCR Purification Kit (#28104; QIAGEN, Hilden, Germany). DNA enrichment was quantified by qRT-PCR. ChIP primer sequences are listed in Supplementary Table 3 .
RNA extraction, cDNA synthesis, and quantitative RT-PCR
RNA was isolated with TRIzol® reagent (#15596018, Invitrogen, Thermo Fisher Scientific, (Ye et al, 2012) . Gene expression was normalized against the expression of TATA-binding protein (Tbp).
Primer sequences are listed in Supplementary Table 2 .
Co-immunoprecipitation (CoIP)
COS A. Co-immunoprecipitation (CoIP) of LXRα and ChREBPα expressed in COS-1 cells cultured in 25 mM glucose. Lysates were immunoprecipitated with ChREBP and LXRα antibodies, and input and immunoprecipitated proteins immunoblotted the same antibodies (n=3). One representative western blot is shown.
B. Distribution of ChREBP-LXR peak pairs. ChREBP ChIP-seq data from fasted and highcarbohydrate refed mouse liver (Poungvarin et al, 2015) and LXR ChIP-seq data from T0901317-treated mouse liver (Boergesen et al, 2012) were reanalyzed to generate a genomewide map of ChREBP and LXR binding sites. The top 10,000 peaks from each dataset were used to calculate the Peak(ChREBP)-to-Peak(LXR) distance, and all peak pairs with a peak-topeak distance < 1,000 bp were plotted against the number of peak pairs.
C. Localization of ChREBP-LXR peak pairs. The Peak(ChREBP)-to-Peak(LXR) distance were plotted against the position relative to transcription start site (TSS) of the closest gene. Blue dots, verified LXR/ChREBP target genes, Acaca, Mlxipl (Chrebpα and β), Pklr, Scd1, Srebf1 and Txnip. Orange curve, moving average (window: 100 bp) of peak-to-peak distance as a function of distance to TSS. G. Genome-wide co-occurrence of mouse hepatic transcription factors (TFs). Comparison of LXR and ChREBP with published binding profiles of PPARα (Boergesen et al, 2012) and FXR (Ijssennagger et al, 2016) . Forbes coefficients (FC) of genomic co-occurrence between ChREBP, LXR, FXR and PPARα were calculated using the Genomic HyperBrowser.
Figure 2. LXRα co-activates ChREBP specific target genes in vitro and in vivo.
A. Huh7 cells cultured in 25 mM glucose were transfected with a Chrebpβ (n=3) or Lpk-driven luciferase reporter (n=6), and plasmids expressing ChREBPα/Mlxγ, with or without LXRα/RXRα. The Renilla luciferase reporter pRL-CMV was used as internal control. Six hours post transfection, cells were treated with 2.5 mM or 25 mM glucose for 18 hours. Dual luciferase reporter assays were performed 24 hours post transfection.
B. LXRαβ wild type (WT), LXRα -/-, LXRβ -/and LXRα -/β -/mice were fasted for 24 hours (white bars) or fasted for 24 hours and refed for 12 hours (black bars) (n=5-8 mice per group).
Hepatic gene expression of Lpk (Pklr), Chrebpβ and Chrebpα was analyzed by quantitative RT-PCR and normalized to Tbp.
Data are presented as mean ± standard error of the mean (SEM). Significant differences are shown as *p < 0.05, **p < 0.01, ***p < 0.001 compared to control within the same treatment, and # p < 0.05, ## p < 0.01, ### p < 0.001 between indicated groups. Data are presented as mean ± SEM (n=3-7). Significant differences are shown as *p < 0.05, **p < 0.01, ***p < 0.001 compared to control within the same ChREBP isoform transfection. ns, not significant. 
Figure 5. Ligand-activated LXR represses ChREBPα activity on ChREBP-specific target genes
Mouse primary hepatocytes were isolated and cultured in either 1 mM glucose (LG) or 25 mM glucose (HG) for 24 hours. For the last 18 hours the cells were treated with either DMSO (0.1%) or GW3965 (10 µM). Expression of (A) DNL genes Acacb, Fasn, Scd1 and (B) ChREBPspecific target genes Chrebpβ (Mlxiplβ), Lpk (Pklr), Txnip and Rgs16 was analyzed by quantitative RT-PCR and normalized to Tbp. Data are presented as mean ± SEM (n=3). Significant differences are shown as *p < 0.05, **p < 0.01, ***p < 0.001 compared to DMSO within the same glucose treatment, and ## p < 0.01, ### p < 0.001 between LG and HG groups. 
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